<DOC>
	<DOCNO>NCT00861029</DOCNO>
	<brief_summary>This Phase I , randomize , double-blind , placebo-controlled , study estimate effect daily oral dose 800 mg pazopanib electrocardiographic parameter ( QTc interval duration ) compare placebo subject solid tumor . Moxifloxacin , serve positive control .</brief_summary>
	<brief_title>VEG111485 : A QTc Study Pazopanib</brief_title>
	<detailed_description>This Phase I , randomize , double-blind , placebo-controlled , parallel group study design estimate effect repeat , daily oral dose pazopanib electrocardiographic parameter particular focus effect cardiac repolarization ( QTc interval duration ) compare placebo subject solid tumor . Moxifloxacin , drug know cause mild QTc interval prolongation , include positive control validate ability study detect small prolongation QTc interval . Digital 12-lead electrocardiogram ( ECGs ) extract continuous ECG recording obtain via Holter monitor . The effect pazopanib moxifloxacin cardiac repolarization compare placebo . This study also assess pharmacokinetic-pharmacodynamic relationship plasma concentration pazopanib metabolite effect , , cardiac repolarization , specifically QT interval .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female , age 18 year old , time signing informed consent . Has histologically cytologically confirm advanced solid tumor malignancy . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . Able swallow retain oral medication . Adequate organ system function . Serum potassium level &gt; 4 mEq/L , magnesium level &gt; 1.7 mg/dL total serum calcium level within normal limit ( albumin &lt; 4.5 g/dL , albumincorrected total serum calcium level within normal limit [ see Appendix 7 ] ) . NOTE : Supplementation permit order meet criterion . Subject retested follow supplementation . Subject woman nonchildbearing potential willing use acceptable contraception . Subject man female partner childbearing potential agrees use contraception . Subject , sexually active , agree continue recommend contraception method duration treatment 28 day follow discontinuation treatment . Capable give write informed consent . The subject able understand comply protocol requirement , instruction protocolstated restriction . Any following ECG finding , QTcF interval &gt; 470 msec , PR interval &gt; 240 msec â‰¤110msec , Bradycardia define sinus rate &lt; 50 beat per minute Cardiac conduction abnormality denote follow : Evidence seconddegree ( type II ) thirddegree atrioventricular block , Evidence ventricular preexcitation , Electrocardiographic evidence complete leave bundle branch block ( LBBB ) , Intraventricular conduction delay QRS duration &gt; 120 msec , Atrial fibrillation , Presence cardiac pacemaker . History one follow cardiovascular condition within past 6 month : Class III IV congestive heart failure define New York Heart Association ( NYHA ) , cardiac angioplasty stenting , myocardial infarction , unstable angina , symptomatic peripheral vascular disease clinically significant cardiac disease . For subject history myocardial infarction ( &gt; 6 month ago ) , congestive heart failure ( &gt; 6 month ago ) prior anthracycline exposure , leave ventricular ejection fraction ( LVEF ) must assess within 28 day prior first dose study drug one follow method : multiple gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) . Subjects measurement LVEF &lt; 50 % exclude participation study . Personal family history longQT syndrome . History clinical evidence CNS metastases leptomeningeal carcinomatosis , except individual previously treat CNS metastasis , asymptomatic , requirement steroid antiseizure medication 2 month prior begin study treatment . Clinically significant gastrointestinal ( GI ) abnormality may affect absorption study drug include , limited : malabsorption syndrome , major resection stomach small bowel . Clinically significant GI abnormality may increase risk GI bleed include , limited : active peptic ulcer disease , know intraluminal metastatic lesion ( ) suspect bleeding , inflammatory bowel disease , ulcerative colitis GI condition increase risk perforation , history abdominal fistula , GI perforation intraabdominal abscess within 28 day prior begin study treatment . Presence uncontrolled infection . Unable unwilling discontinue use prohibit medication list Section 9.2 least 14 day prior first dose study drug ( see Section 9.2 ) . Poorly control hypertension [ systolic blood pressure ( SBP ) &gt; 140 mmHg , diastolic blood pressure ( DBP ) &gt; 90 mmHg ] . History cerebrovascular accident , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Evidence active bleeding bleed diathesis . Hemoptysis within 6 week prior first dose study drug . Known endobronchial lesion ( ) involvement large pulmonary vessel ( ) tumor . History sensitivity allergic reaction moxifloxacin member quinolone class antimicrobial agent . Treatment anticancer therapy ( include chemotherapy , radiation therapy , immunotherapy , biologic therapy , investigational therapy , hormonal therapy , surgery tumor embolization ) within 14 day prior first dose pazopanib . History presence hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . Prior major surgery trauma within past 28 day prior first dose study drug and/or presence nonhealing wound , fracture ulcer . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , obtain informed consent compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>GW786034 , pazopanib , moxifloxacin , ECG interval morphology , QTc , Holter monitor , pharmacokinetics , safety , cancer</keyword>
</DOC>